Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
about
Pharmacotherapies for obesity: past, current, and future therapiesAn Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for ObesityTargeting NADPH oxidases in vascular pharmacologyObesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorshipEndocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? YesRimonabant-induced depression in schizophrenia.Molecular pathways in non-alcoholic fatty liver disease.The endocannabinoid system: potential for reducing cardiometabolic riskMarijuana-based drugs: innovative therapeutics or designer drugs of abuse?Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in ratsBlood lipids and adipokines concentrations during a 6-month nutritional and physical activity intervention for metabolic syndrome treatment.Pharmacological and non-pharmacological interventions to influence adipose tissue function.Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategiesThe psychiatric side-effects of rimonabant.Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.Greasing the wheels of managing overweight and obesity with omega-3 fatty acids.Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.Cannabis and psychopathology: The meandering journey of the last decadeContributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.Endocannabinoids and related lipids in blood plasma following touch massage: a randomised, crossover study.High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.Does rimonabant independently affect free fatty acid and glucose metabolism?Pharmacotherapy for childhood obesity: present and future prospects.Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation.Rimonabant in rats with a metabolic syndrome: good news after the depression.The endocannabinoid system: role in energy regulationEffects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.Targeting the endocannabinoid system: to enhance or reduce?CB1 cannabinoid receptor inhibition: promising approach for heart failure?Role of endocannabinoid signaling in anxiety and depression.Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding.Cannabinoids and appetite: food craving and food pleasure.Peripheral mechanisms in the control of appetite and related experimental therapies in obesity.Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice.
P2860
Q21296814-864697E5-BBA1-463E-A09D-463F2582B958Q26767356-DD688C48-085D-4918-AA11-C538AD330C7FQ26863500-0D01E741-7861-452B-AB99-950A4A324B2CQ28475155-4750831E-55FE-4A78-8DDC-87A7146C6390Q30473707-22144B28-4970-4E7E-B6E8-9958E5CB11C5Q33509626-D5FD99B8-94B6-4560-9449-9E7580B777D8Q33610682-3773E3D2-0A3E-45DB-A56B-5188F84E8A8BQ33692174-63C0FB03-297E-4A59-BFFC-A72B95D8C4DDQ33890230-F43815A5-BF38-47E9-ABFF-C3FD9A9290F2Q33999727-DCCABD4D-C405-4C5D-84B1-193F2D378642Q34173626-49BE2944-75F2-44B8-BE27-F3FCAD731999Q34292608-F728B011-A327-4339-B9A6-71AFF9F5CCB8Q34499487-D935FE22-8E07-4291-BCCB-9ADEC9BE2520Q34576535-A3031623-DC71-48A1-8CB9-3C1FCBBC1222Q34657286-E35B14EE-1708-4920-96D7-486FC18114DFQ34990771-3902D7EE-43A7-4FE8-A0FE-85CD590740F7Q35107668-8026A5F6-21D8-442B-BF17-63C230885978Q35442310-ED618956-FB10-4DD7-AB1B-DEDD33F6869AQ35534153-D8DAE43D-B85F-4AE4-BAA4-DE18629565D6Q35672654-93B717DB-4840-477C-BD6F-250DA167A03CQ35716762-EE1E417B-49B9-4606-A77B-D83D6F793A01Q35784024-B659CA1C-3FDC-441B-BBEB-BD9687E82F74Q35792553-54B882FE-FC6A-4D99-87FB-56B0A80E526EQ35844499-36A8EF0E-47EF-4614-868A-043955095198Q35849373-8B950847-B0B6-4EDC-AF2C-EEECBDCAE855Q35869688-596B4569-B04B-4CEA-BE3B-F8DC40A8401AQ36468087-70F9382F-20A3-4630-9999-28BA26F81573Q36473356-DABDFA08-83F7-4C6A-89F4-6BE678767137Q36753588-AEC4A005-1218-48F3-A0E8-C420A2DF74B9Q36966693-D29F98F6-88AF-4D86-BE23-A4D1A85A287CQ37029513-E8C8C426-DFD5-4DF1-8D78-767B59D5FBCEQ37143614-E7A34C74-E59E-449D-9B75-933B551A3369Q37150745-A5151359-5836-4E84-A289-CEBEFD4094BDQ37160279-236407F8-6997-451C-8A9F-40271F37AD00Q37254797-325A0B65-DDE3-45B7-A1FB-52AD6B7755B9Q37376946-E353984E-C6CA-403C-B2FC-1352AEE1BE9BQ37444818-D1717C1C-3031-458E-AEDB-B61C16CF9B6FQ37467184-6B8F7EBD-298E-4CAF-97D7-063DE8901A19Q37581457-B1CDC81B-056F-43AB-96BD-7C191B3BE50EQ37593467-E1C99250-A6C0-4747-81FD-80DDFD776BD1
P2860
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacy and safety of rimonab ...... bant in Obesity (RIO) program.
@ast
Efficacy and safety of rimonab ...... bant in Obesity (RIO) program.
@en
type
label
Efficacy and safety of rimonab ...... bant in Obesity (RIO) program.
@ast
Efficacy and safety of rimonab ...... bant in Obesity (RIO) program.
@en
prefLabel
Efficacy and safety of rimonab ...... bant in Obesity (RIO) program.
@ast
Efficacy and safety of rimonab ...... bant in Obesity (RIO) program.
@en
P2093
P356
P1433
P1476
Efficacy and safety of rimonab ...... bant in Obesity (RIO) program.
@en
P2093
André Scheen
Christine McCarthy
Luc Van Gaal
P304
P356
10.2337/DC08-S258
P407
P478
31 Suppl 2
P577
2008-02-01T00:00:00Z